HK1047050A1 - 治疗轻度智力机能缺陷的方法 - Google Patents

治疗轻度智力机能缺陷的方法 Download PDF

Info

Publication number
HK1047050A1
HK1047050A1 HK02108738.8A HK02108738A HK1047050A1 HK 1047050 A1 HK1047050 A1 HK 1047050A1 HK 02108738 A HK02108738 A HK 02108738A HK 1047050 A1 HK1047050 A1 HK 1047050A1
Authority
HK
Hong Kong
Prior art keywords
methods
cognitive impairment
mild cognitive
treating mild
receptor antagonist
Prior art date
Application number
HK02108738.8A
Other languages
English (en)
Chinese (zh)
Inventor
F. Schatzberg Alan
K. Belanoff Joseph
Original Assignee
Corcept Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22607362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1047050(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Corcept Therapeutics Inc. filed Critical Corcept Therapeutics Inc.
Publication of HK1047050A1 publication Critical patent/HK1047050A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK02108738.8A 1999-11-23 2000-11-21 治疗轻度智力机能缺陷的方法 HK1047050A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16743299P 1999-11-23 1999-11-23
US167432P 1999-11-23
PCT/US2000/032260 WO2001037840A1 (en) 1999-11-23 2000-11-21 Methods for treating mild cognitive impairment

Publications (1)

Publication Number Publication Date
HK1047050A1 true HK1047050A1 (zh) 2003-02-07

Family

ID=22607362

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02108738.8A HK1047050A1 (zh) 1999-11-23 2000-11-21 治疗轻度智力机能缺陷的方法

Country Status (7)

Country Link
US (2) US6620802B1 (https=)
EP (1) EP1242094A4 (https=)
JP (1) JP2003527342A (https=)
AU (1) AU778090B2 (https=)
CA (1) CA2389570C (https=)
HK (1) HK1047050A1 (https=)
WO (1) WO2001037840A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010046470A1 (en) * 2000-05-10 2001-11-29 Kieko Morita Diagnoses and treatment of disorders using an alternative glucose pathway
DE60232956D1 (de) 2001-03-23 2009-08-27 Corcept Therapeutics Inc Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
NZ531477A (en) * 2001-08-31 2006-10-27 Corcept Therapeutics Inc Use of a glucocorticoid receptor antagonist comprising a steroidal skeleton with at least one phenyl-containing moiety in the 11-beta position of the steroidal skeleton to decrease cognitive deterioration in adults with Down's syndrome
JP2005528395A (ja) * 2002-04-05 2005-09-22 ザ ユニバーシティ オブ エディンバラ 組成物
US8237946B2 (en) * 2004-10-08 2012-08-07 Sharp Laboratories Of America, Inc. Methods and systems for imaging device accounting server redundancy
US20090156565A1 (en) * 2004-12-03 2009-06-18 The Children's Hospital Of Philadelphia Composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
DK3260118T3 (da) * 2008-10-16 2021-04-19 Univ Johns Hopkins Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US20150290158A1 (en) * 2012-11-09 2015-10-15 Elliott C. Lasser X-ray contrast media compositions and methods of using the same to treat, reduce or delay the onset of cns inflammation and inflammation associated conditions
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3337450A1 (de) * 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
EP0954317B1 (en) 1996-04-09 2007-06-06 The University Of Edinburgh Use of 7 apha-substituted steroids to treat neuropsychiatric disorders
AU747956B2 (en) * 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
IL139672A (en) * 1998-05-15 2005-11-20 Univ Leland Stanford Junior Glucocorticoid receptor antagonists for the tretment of dementia

Also Published As

Publication number Publication date
JP2003527342A (ja) 2003-09-16
WO2001037840A1 (en) 2001-05-31
US6620802B1 (en) 2003-09-16
AU778090B2 (en) 2004-11-18
EP1242094A4 (en) 2004-06-16
US20040019028A1 (en) 2004-01-29
CA2389570C (en) 2012-03-27
CA2389570A1 (en) 2001-05-31
EP1242094A1 (en) 2002-09-25
AU1928301A (en) 2001-06-04

Similar Documents

Publication Publication Date Title
CA2328411A1 (en) Glucocorticoid receptor antagonists for the treatment of dementia
IL159913A0 (en) Methods for preventing antipsychotic-induced weight gain
WO2002076390A3 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
CA2302586A1 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
HK1047050A1 (zh) 治疗轻度智力机能缺陷的方法
NO20003534L (no) Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
WO2002008221A3 (en) Capsaicin receptor ligands
WO2002079221A3 (en) Sapogenin derivatives, their synthesis and use
IL160649A0 (en) Methods for inhibiting cognitive deterioration in adults with down syndrome
MXPA04010705A (es) Metodos para incrementar la respuesta terapeutica a la terapia electroconvulsiva ("ect").
WO2004069202A3 (en) Antiglucocorticoids for the treatment of postpartum psychosis
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
IL158744A0 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
EP1726307A3 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
WO2002020526A3 (en) Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents